| Literature DB >> 22573913 |
Eric M Reiman1, Roberta Diaz Brinton, Russell Katz, Ronald C Petersen, Selam Negash, Dan Mungas, Paul S Aisen.
Abstract
What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22573913 PMCID: PMC3391068 DOI: 10.1093/gerona/gls124
Source DB: PubMed Journal: J Gerontol A Biol Sci Med Sci ISSN: 1079-5006 Impact factor: 6.053